

Amendments to the Claims

Please amend Claim 97, and cancel Claims 101-155. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-96 Cancelled

97. (Currently Amended) A method for displaying an autodeterminant peptide, in association with a MHC class II protein, on the surface of a MHC class II-positive antigen presenting cell, comprising:
- a) providing the MHC class II-positive antigen presenting cell which does not contain an exogenous construct encoding mammalian B7 molecule; and
 - b) introducing into the MHC class II-positive antigen presenting cell, a specific regulator of li protein expression or immunoregulatory function, the oligonucleotide 3'-CTCGGTACCTACTGG-5' (SEQ ID NO: 1) being specifically excluded, the specific regulator consisting essentially of a copolymer of from 10 to 50 nucleotide bases, the copolymer being characterized by the ability to hybridize specifically to a target region of the RNA molecule encoding mammalian li protein under physiological conditions, wherein the specific regulator is characterized by the ability to inhibit li expression.
98. (Original) The method of Claim 97 wherein the specific regulator of li is introduced into the MHC class II-positive antigen presenting cell via electroporation.
99. (Original) The method of Claim 97 wherein the target region comprises the translation initiation site of the RNA molecule encoding mammalian li protein.
100. (Original) The method of Claim 99 wherein the specific regulator comprises a nucleotide base sequence selected from the group consisting of SEQ ID NOS: 54, 53, 52, 40 and 55.

101-155 Cancelled